Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02672865 · ClinicalTrials.gov registry record · Phase 1

Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer

A Phase 1 study, sponsored by Loma Linda University.

Completed
Registry status
Phase 1
Development phase
4
Enrollment target

NCT02672865: Completed Phase 1 study, sponsored by Loma Linda University.

NCT02672865 is a Phase 1 study that has completed, run by Loma Linda University. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02672865, a Phase 1 study, has completed, sponsored by Loma Linda University.

COMPLETED
Registry status
Phase 1
Development phase
4 participants
Enrollment target

Study Summary

The purpose of this study is to determine safety and feasibility of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin and cisplatin in patients with locally advanced gastric cancer undergoing standard surgical resection. Patients will be treated with HIPEC using a single dose of mitomycin 15mg/m2 and cisplatin 50mg/m2 at 41-42 C for 90 minutes, during the definitive surgical resection for gastric cancer. HIPEC will be performed after resection but before anastomosis.

Primary Outcome

Patients will be followed for 90 days following surgery. Postoperative complications will be recorded and graded according to the modified Clavien-Dindo classification.

Interventions

  • DRUG Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2016-02-02
Est. Completion 2018-10-03
Phase Phase 1
Loma Linda University

237 total trials

What the finished NCT02672865 record still lists

NCT02672865 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 1 intervention - of which Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the first listed.

NCT02672865 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02672865 about?

NCT02672865 is a clinical study titled "Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer". The purpose of this study is to determine safety and feasibility of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin and cisplatin in patients with locally advanced gastric cancer undergoing standard surgical resection. Patients will be treated with HIPEC using a single dose...

What is the current status of trial NCT02672865?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2016-02-02. Estimated completion is 2018-10-03.

What interventions are being tested in trial NCT02672865?

The interventions under investigation include: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (DRUG).

Who is sponsoring clinical trial NCT02672865?

This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02672865's enrollment target sits among peer trials

4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02672865, the US trial registry maintained by the National Library of Medicine. NCT02672865 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.